Gritstone, Gilead Partner To Develop Therapeutic HIV Vaccine
Deal Closely Follows COVID-19 Vaccine Effort
Gritstone will supply the same type of prime-boost vaccine technology it is applying to SARS-CoV-2, and Gilead will supply its own antigens, with the goal of curing HIV.
You may also be interested in...
Another vaccine failure shows that HIV’s ability to “attack, hijack and evade” the human immune system is still outwitting researchers, but J&J will continue with Phase III study of a related vaccine.
Sales of COVID-19 drug Veklury helped keep sales in the black as the pandemic and generic competition weighed on HIV and HCV products; Gilead raised full-year 2021 guidance.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.